20,975 Shares in Agilent Technologies, Inc. (NYSE:A) Acquired by Entropy Technologies LP

Entropy Technologies LP purchased a new stake in Agilent Technologies, Inc. (NYSE:A) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 20,975 shares of the medical research company’s stock, valued at approximately $3,114,000.

Other institutional investors have also modified their holdings of the company. Livelsberger Financial Advisory purchased a new position in Agilent Technologies in the third quarter valued at $28,000. Crewe Advisors LLC boosted its stake in shares of Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after buying an additional 101 shares during the period. Ashton Thomas Securities LLC acquired a new position in shares of Agilent Technologies during the third quarter worth about $31,000. Ridgewood Investments LLC purchased a new stake in shares of Agilent Technologies during the second quarter worth approximately $29,000. Finally, Fortitude Family Office LLC raised its holdings in Agilent Technologies by 68.3% in the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 95 shares in the last quarter.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,995 shares of company stock valued at $1,739,510 over the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have commented on A. Evercore ISI increased their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Bank of America raised their price target on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Barclays upped their price objective on Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a research report on Tuesday, October 15th. UBS Group raised their target price on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $151.00 price target on shares of Agilent Technologies in a report on Monday, August 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $144.36.

Agilent Technologies Stock Performance

NYSE A opened at $133.86 on Tuesday. The business’s 50-day moving average price is $139.46 and its 200 day moving average price is $138.21. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The firm has a market cap of $38.46 billion, a P/E ratio of 27.77, a P/E/G ratio of 6.01 and a beta of 1.07. Agilent Technologies, Inc. has a 52-week low of $106.96 and a 52-week high of $155.35.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the previous year, the company posted $1.43 earnings per share. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. On average, equities research analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were paid a $0.236 dividend. This represents a $0.94 annualized dividend and a dividend yield of 0.71%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 19.50%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.